sofosbuvir + ribavirin + natural anti-hemolytic

This is a combination therapy consisting of sofosbuvir, ribavirin, and an unspecified "natural anti-hemolytic." Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, essential for viral replication. Ribavirin is a nucleoside analog with broad-spectrum antiviral activity that enhances the efficacy of direct-acting antivirals like sofosbuvir but can cause hemolytic anemia as a side effect. The addition of a "natural anti-hemolytic" suggests an attempt to mitigate ribavirin-induced hemolysis; however, no specific natural compound with established clinical use for this purpose in HCV therapy has been identified in standard medical practice or regulatory approvals. This combination would be experimental and not recognized as standard care.